– Presented key product lines spanning aesthetic, wound care, bone and spine, and surgical fields
– Signed supply agreements totaling KRW 5.3 billion with partners from Singapore, Malaysia, Pakistan, Taiwan, and the Philippines

SEOUL, South Korea, April 7, 2026 /PRNewswire/ — CGBIO (CEO Hyunseung Yu), a biotechnology company specializing in regenerative medicine, announced on the 6th that it participated in the 41st Korea International Medical & Hospital Equipment Show (KIMES 2026), recently held at COEX in Seoul, where it showcased products across aesthetic, wound care, bone and spine, and surgical fields, and signed overseas supply contracts worth a total of KRW 5.3 billion with partners from five countries.

KIMES is a leading medical device and hospital equipment exhibition that brings together healthcare professionals, industry stakeholders, and domestic and international buyers to explore the latest medical technologies and market trends. At this year’s exhibition, CGBIO focused not only on introducing individual products but also on presenting its integrated solution competitiveness by connecting its core product portfolio.

At the forefront of the exhibition were key products including FACETEM (aesthetic), Curasys ME (wound care), NOVOSIS (bone substitute), and CG GEL (endoscopic hemostatic agent).

FACETEM is a collagen stimulator that goes beyond a conventional filler by inducing collagen production within the body, addressing the global aesthetic market’s growing emphasis on natural volume enhancement and skin regeneration. Curasys ME is a next-generation negative pressure wound therapy (NPWT) device designed with both medical professionals and patient convenience in mind, offering a more efficient wound care environment. NOVOSIS, known for its superior osteoinductive performance, represents CGBIO’s technological competitiveness in the bone and spine segment. CG GEL, an endoscopic hemostatic agent, demonstrated its applicability in surgical and procedural settings by effectively controlling bleeding during endoscopic interventions.

In addition, CGBIO exhibited a wide range of products across various segments, including AILEENE, GISELLELIGNE, LUXX, DOOTH, Curasys2, CuraVAC Double Channel, BELUNA, NOVOMAX, Verteon, EXCENDER, CUVIS-Spine, Solendos Endo Tower, Realist Bone Model, ARISTENT, and NOVONIX.

During the exhibition, CGBIO strengthened its foundation for global market expansion by proposing tailored strategies that reflect country-specific healthcare environments and partner needs. Through on-site consultations, the company expanded engagement with overseas buyers by explaining the clinical value and applicability of each product line.

Contract signing ceremonies with overseas partners were also held during the exhibition period. CGBIO signed exclusive supply agreements with Neuva Era for FACETEM in Singapore and Malaysia, and with MediNova Healthcare for exclusive distribution of FACETEM in Pakistan. Additionally, the company entered into a supply agreement with HCT Regenerative Co., Ltd. for CGDerm One-Step in Taiwan, and with Variance Trading Corporation for wound care solution products including Curasys, CuraVAC, EasyFoam, and Easydew MD Cream in the Philippines.

Hyunseung Yu, CEO of CGBIO, stated, “KIMES 2026 served as an opportunity for CGBIO to demonstrate its competitiveness as a comprehensive medical device solution provider, moving beyond a single-product focus.” He added, “We will continue to expand our overseas business foundation through strategic product proposals and partnerships tailored to the needs of each market and partner.”

• Hyundai Motor initiates global naming of sea forests across Korea, Argentina and Australia
• Campaign highlights the climate value of marine ecosystems through naming and identity-building during Earth Month
• Dedicated website and mapping registrations aim to build global awareness and data access
• Ongoing marine conservation includes Ulsan sea forest restoration projects conducted in partnership with Korean government agencies

SEOUL, South Korea , April 7, 2026 /PRNewswire/ — Hyundai Motor Company today announced the global launch of its ‘Forests Without Names’ campaign, an initiative that celebrates Earth Month this April by naming sea forests worldwide while highlighting their environmental importance.

The campaign aims to increase awareness of these often overlooked underwater ecosystems and reinforce Hyundai Motor’s long-term marine conservation efforts, including seaweed-based sea forest restoration off the coast of Ulsan, South Korea, and marine waste cleanup projects spanning 10 countries.

“Hyundai Motor Company has been committed to forest conservation across both terrestrial and marine ecosystems. Through the ‘Forests Without Names’ campaign, we are pleased to shed light on sea forests and highlight their ecological value and the importance of protecting our marine environments. We are especially proud to bring this story to life creatively — sparking curiosity about what has long gone unnoticed, and inspiring people to care about what they now know by name. We will continue to advance our sustainability efforts in pursuit of a more environmentally responsible future.”
 – Hyunchul Jeon, Head of Future Business & Sustainability Group at Hyundai Motor Company

What Are Sea Forests and Why Do They Matter?

Sea forests are underwater ecosystems formed by dense marine algae such as kelp and seaweed. Like terrestrial forests, they provide habitats, filter marine pollutants and support coastal biodiversity.

Global scientific and policy interest in seaweed’s climate value increased in 2025, as discussions at the IPCC’s 63rd Session in Lima highlighted the need to explore methodological pathways for including seaweed in future carbon accounting frameworks.

Why Is Hyundai Naming Sea Forests?

Unlike iconic terrestrial forests, many sea forests have no formal names — anonymity that limits their visibility and the protection they receive. The campaign addresses this fundamental gap by giving these ecosystems clear identities.

Finalized names will be added to the campaign’s Sea Forest Map, which Hyundai Motor ultimately aims to integrate with widely used global mapping platforms and leading Korean platforms including Kakao Map. Hyundai Motor brings the public directly into the process through open voting — driving a shift in environmental communication from awareness alone toward recognition, documentation and long-term protection.

How Does the ‘Forests Without Names’ Campaign Work?

The campaign builds on Hyundai Motor’s earlier environmental storytelling initiatives, including the Cannes Lions-winning ‘Tree Correspondents’ campaign in 2025, which used artificial intelligence (AI) to give trees a voice and spotlight the importance of forest conservation.

This new initiative expands Hyundai Motor’s sustainability focus from land ecosystems to marine environments through three main actions:

• Naming three sea forests worldwide:
• • Korea: One of the two restored sea forests in Ulsan is officially named “Ullim” — a Korean word evoking resonance or an echo — through a formal naming process conducted in close collaboration with the Ministry of Oceans and Fisheries and the Korea Fisheries Resources Agency (FIRA).
  • Argentina: Hyundai has designated an official sea forest name “Auken Aiken” meaning “Field of Life” in the local indigenous language through a partnership with a local NGO specialized in marine conservation and community groups.
  • Australia: The final name will be determined through a public voting process conducted via Hyundai Motor’s global social channels and campaign website, with shortlisted candidates selected jointly with local NGOs and community groups.
• Registering these sites on a dedicated campaign website and mapping platform such as ‘Kakao Map’, with the ambition to expand to global platforms
• Working closely with the Korean government, NGOs and local communities to ensure scientific credibility and long-term conservation outcomes

The dedicated campaign website will evolve into a global Sea Forest Data Hub, archiving verified information such as location, ecosystem characteristics, and restoration activities. By making this data publicly accessible, Hyundai aims to build one of the world’s most comprehensive open databases on underwater forests.

What Will Happen During Earth Month?

Key milestones include:

• April 3
  • Release of teaser campaign video and open campaign website
  • Announcement of sea forest names in Korea and Argentina, alongside public voting in Australia
• April 22 (Earth Day): Release of main campaign film and announcement of Australia’s final sea forest name

Finalized names will be added to the campaign’s Sea Forest Map, with the goal of registering these sea forests on global mapping platforms in the future.

How Does This Connect to Hyundai Motor’s Broader Marine Conservation Work?

The naming initiative is part of Hyundai Motor’s longer-term environmental strategy rather than a standalone campaign.

Hyundai Motor has been restoring seaweed forests in Ulsan since 2024 under agreements with Korea’s Ministry of Oceans and Fisheries, the Korea Fisheries Resources Agency and Ulsan Metropolitan City. The project spans approximately 3.96 square kilometers and is expected to offset about 1,300 tons of CO₂ annually through carbon absorption and ecosystem restoration, through methods including seaweed transplantation, spore dispersal, artificial underwater longline installations, local species reproduction support and seabed cleanup.

Meanwhile, since 2021, the company has conducted marine waste collection projects in partnership with the Healthy Seas foundation across Europe, Korea and the United States. These efforts have resulted in the removal of approximately 320 tons of marine debris, including discarded fishing nets later recycled into ECONYL^® nylon fiber used in vehicle materials such as floor mats for IONIQ 5, IONIQ 6, IONIQ 9, INSTER, SANTA FE and NEXO models sold in Europe.

Hyundai Motor aims to support ecosystem recovery and realize potential climate mitigation benefits through these initiatives.

About Hyundai Motor Company

Established in 1967, Hyundai Motor Company is present in over 200 countries with more than 120,000 employees dedicated to tackling real-world mobility challenges around the globe. Based on the brand vision ‘Progress for Humanity,’ Hyundai Motor is accelerating its transformation into a Smart Mobility Solution Provider. The company invests in advanced technologies such as robotics and Advanced Air Mobility (AAM) to bring about revolutionary mobility solutions while pursuing open innovation to introduce future mobility services. In pursuit of a sustainable future for the world, Hyundai will continue its efforts to introduce zero-emission vehicles with industry-leading hydrogen fuel cell and EV technologies.

More information about Hyundai Motor and its products can be found at:
https://www.hyundai.com/worldwide/en/ or Newsroom: Media Hub by Hyundai

Follow our Hyundai Global Newsroom Instagram channel @hyundai media hub

Visit the Hyundai Media Hub for more content

TAIPEI, April 7, 2026 /PRNewswire/ — In a robust nod to sustainability innovation, Hon Hai Technology Group (“Foxconn”) (TWSE:2317) has honored 152 teams and projects at the “2026 Hon Hai-Foxconn Sustainability Awards”, an in-house distinction that accelerates the work of the world’s largest electronics manufacturer and leading technology solutions provider to innovate for the good.

Recognizing environmental, social and governance, across Asia, Americas and Europe, the scale and impact of the Sustainability Awards continue to grow, attracting 1,504 entries from Foxconn teams in its third year – five times more than its inaugural edition. Nitrogen safety in Vietnam, zero-carbon cleaning in China and exoskeleton-assisted equipment in the Czech Republic were among projects celebrated, demonstrating deepening of ESG capabilities.

“Through the Sustainability Awards platform, Foxconn colleagues around the world can share outcomes of ESG initiatives. This also encourages all units to transform innovative practices into tangible results, making sustainability not just a goal, but a part of daily operations,” said Foxconn Chairman Young Liu. The awards ceremony this year was held at the Shenzhen campus, a World Economic Forum-designated Lighthouse factory site.

Nearly 500 colleagues and supply-chain partners from the Group’s operations worldwide attended, in person and online. This year’s event recognized innovative achievements of the Group’s supply chain, such as at STMicroelectronics, Murata Manufacturing Co and Winbond Electronics Corp, while engaging in a summit roundtable to hear their views about Foxconn’s sustainability development.

Winners showcased diverse innovations:

• Czech Republic: Introduction of exoskeleton-assisted equipment to improve working posture and reduce occupational injury risks, which earned its own recognition in the Czech Republic this year.
• US: Amid operational expansion in the key market, US operations integrated management processes through digital platforms to enhance operational efficiency and governance transparency.
• India: Water-saving advocacy, rainwater harvesting and wastewater reuse recognized in comprehensive program for improved water-use efficiency.
• Vietnam: Improved cost control through nitrogen safety optimization.
• China: Reduction in electricity costs and carbon emissions through zero-carbon cleaning improvements.

The selection process included document review, jury panel discussions and external evaluation, spanning three rounds and involving up to 100 judges. External experts, scholars, and professional organizations joined in-house judges this year. Following more than two months of evaluation, 332 entries were shortlisted based on different ESG domains and categories.

About Foxconn here.

MELBOURNE, Australia and INDIANAPOLIS, April 7, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides a market update on its commercial and operational performance for the quarter ended March 31, 2026 (Q1 2026).

Q1 2026 Highlights

• Q1 2026 unaudited Group revenue of US$230 million, up 11% quarter-over-quarter.

• FY 2026 revenue guidance of US$950 million to US$970 million is reaffirmed.

• Precision Medicine Q1 2026 unaudited revenue of US$186 million, up 16% quarter-over-quarter. Strong revenue growth in both Illuccix® and Gozellix® segments.

• ProstACT® Global Phase 3 study of TLX591-Tx prostate cancer therapy candidate: Part 1 lead-in met safety and dosimetry objectives, with no new safety signals observed^[1].

• TLX101-Px (brain cancer imaging candidate): New Drug Application (NDA) resubmitted to the United States (U.S.) Food and Drug Administration (FDA)^[2] for Pixclara®^[3]. Marketing Authorization Application (MAA) filed in Europe^[4] for Pixlumi®³.

• TLX591-Px^[5]: NDA accepted in China by the National Medical Products Administration (NMPA)^[6].

Q1 2026 Revenue (Unaudited)

Executive Commentary

Dr. Christian Behrenbruch, Managing Director and Group CEO, stated, “Growth accelerated across our Precision Medicine business in the first quarter, with U.S. dose volumes increasing 5% quarter-over-quarter. This performance reflects the growing uptake of Gozellix alongside Illuccix, contributing to market share gains underpinned by disciplined sales execution and pricing, and high-quality service delivery despite extreme North American weather conditions, an advantage of the pharmacy distribution model. With our two‑product PSMA^[9] imaging strategy, differentiated clinical positioning and expanding commercial presence globally, we are seeing a solid foundation for continued growth through 2026. Importantly, we are delivering on our strategic priorities to advance our high-value clinical programs, demonstrated by the momentum in our therapeutics pipeline this quarter.”

Therapeutics Business Unit

Telix continues to progress its industry-leading Therapeutics pipeline, which spans multiple product candidates and disease areas. Q1 2026 highlights include:

• TLX591-Tx (lutetium (¹⁷⁷Lu) rosopatamab tetraxetan): Part 1 of ProstACT Global, the Phase 3 trial of its lead prostate cancer therapy candidate, achieved its study objectives, demonstrating an acceptable safety and tolerability profile with no new safety signals observed¹. No adverse drug-drug interactions were observed in TLX591-Tx combinations, demonstrating the feasibility of integrating TLX591-Tx with current standard of care therapies for mCRPC^[10], including ARPIs^[11] (enzalutamide or abiraterone) and docetaxel. Telix has commenced engagement with the FDA to present data from Part 1 and ascertain eligibility for U.S. patients to participate in Part 2 (randomized treatment expansion). Part 2 is open for enrollment in Australia, New Zealand and Canada, with site activation underway in preparation to open enrollment in China, Singapore, South Korea, Türkiye, the United Kingdom and Japan, where regulatory approvals have already been granted.

• TLX250-Tx (lutetium (¹⁷⁷Lu) girentuximab tetraxetan): Telix has opened its first clinical site and is recruiting patients for Part 1 of LUTEON^[12], a pivotal trial of TLX250-Tx as a monotherapy in advanced ccRCC^[13]. Trial recruitment will initially focus ex-U.S.

• TLX101-Tx (¹³¹I-iodofalan): Telix has enrolled the first patient in IPAX-BrIGHT, an international, multi-center pivotal trial of TLX101-Tx in patients with recurrent glioblastoma^[14]. The trial is now open for enrollment in Australia, Austria and the Netherlands and has received regulatory approval to commence in Belgium.

• TLX090-Tx (¹⁵³Sm-DOTMP): Telix continues to dose patients in SOLACE^[15], a Phase 1 study of a drug candidate for treating pain in patients with osteoblastic bone metastases from prostate and breast cancers. The study was expanded this quarter to include additional U.S. sites to accelerate recruitment. 

• TLX597-Tx (¹⁷⁷Lu-DOTA-HYNIC-panPSMA): TLX597-Tx is a “next generation” PSMA-targeting prostate cancer therapy candidate being developed to facilitate patient access in select geographies, where routine clinical availability to approved therapies is limited or not available. Early clinical data suggests a favorable asset biodistribution with limited uptake in healthy organs of concern (e.g., salivary glands, kidneys) relative to available ¹⁷⁷Lu-PSMA therapies. Interim data from OPTIMAL-PSMA^[16], an investigator-led, randomized, dose intensification study of TLX597-Tx in mCRPC, will be presented at the International Prostate Cancer Symposium in April 2026. 

Precision Medicine Business Unit

PSMA imaging portfolio:

• Telix continues to expand its commercial footprint with Illuccix now launched in 21 countries globally, which includes 16 countries in Europe. This growing international presence enhances access to PSMA-PET/CT imaging^[17] while establishing a scalable commercial and operational platform to support future product launches, including follow-on therapeutic products.

• Telix’s broad proposed label for TLX591-Px (Illuccix) is under review by the NMPA Centre for Drug Evaluation as part of the NDA submission^[18].

TLX101-Px, (Floretyrosine F 18 or ¹⁸F-FET):

• Telix has resubmitted its NDA in the U.S. with the additional clinical data and analysis as agreed with the FDA.

• Telix has submitted a MAA in Europe covering commercially significant markets, seeking to expand patient access to advanced brain imaging.

Zircaix®³ (TLX250-Px, ⁸⁹Zr-DFO-girentuximab):

• Based on two successful Type A meetings with the FDA, Telix believes it has aligned on key outstanding issues for the Biologics License Application (BLA) resubmission, including demonstration of drug product comparability between clinical trial material and scale-up commercial production. The Company is now completing the agreed deliverables and documentation required, targeting a H1 2026 submission.

Corporate Updates

Telix has announced the appointment of David Gill as Non-Executive Director (NED), effective May 11, 2026, as part of its Board renewal process^[19]. Mr. Gill is expected to be appointed as Chair in due course, succeeding Dr. Mark Nelson who will remain on the Board as NED. The Board believes Mr. Gill’s appointment will enhance the Board’s capability, with extensive experience in U.S. public company governance, financial oversight and senior leadership across commercial and clinical-stage biopharmaceutical companies.

FY 2026 guidance

• Telix reaffirms FY 2026 revenue guidance of US$950 million to US$970 million^[20].

• Guidance reflects revenue from product sales in jurisdictions with a marketing authorization, and a full year of revenue contribution from RLS.

• Telix reaffirms research and development (R&D) expenditure guidance of US$200 million to US$240 million, subject to achieving ongoing global commercial milestones.

About Telix Pharmaceuticals Limited

Telix is a global biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Illuccix (kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection) has been approved by the FDA^[21], and in multiple markets globally. Gozellix (kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection) has been approved by the FDA^[22]. No other Telix product mentioned in this announcement has received a marketing authorization in any jurisdiction.

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

Guidance Disclaimer

The stated revenue guidance is based on expected global and domestic economic conditions and is subject to known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially. As such, investors are cautioned not to place undue reliance on this guidance and in particular Telix cannot guarantee a particular result. In compiling financial forecasts, a number of key variables that may have a significant impact on guidance have been identified and are listed below.

Key variables that could cause actual results to differ materially include: the success and timing of research and development activities; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation, regulation, or policy that affects product production, distribution, pricing, reimbursement, access or tax; acquisitions and divestitures; research collaborations; litigation or government investigations; and Telix’s ability to protect its patents and other intellectual property. See the Legal Notices section below for additional information, risks and assumptions.

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including TLX101-Px and TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

SYDNEY, April 7, 2026 /PRNewswire/ — RETOPIA SALON, an entertainment company founded by key former executives from HYBE who played a pivotal role in BTS’s global success, is launching a search for the next generation of K-pop talent in Australia.

The company will host the “2026 RETOPIA SALON GLOBAL AUDITION: AUSTRALIA” across Sydney, Melbourne, and Brisbane this May. The audition schedule is as follows:

• May 13 – Sydney, IX Dance Studio
• May 17 – Melbourne, X-Dance Station and O2 KPOP ACADEMY
• May 19 – Brisbane, XPACE STUDIO BRISBANE
• May 20 – Gold Coast, YJ DANCE SCHOOL GOLD COAST

Applicants born between 2008 and 2014 are eligible to participate regardless of gender or nationality. Participants may choose one category to audition in: vocal, rap, dance, or acting.

“We aim not only to select the final members of our first boy group set to debut in 2027, but also to discover hidden talent for future girl group projects,” said RETOPIA SALON. “We look forward to passionate applicants from around the world who dream of becoming global stars.”

Beyond Australia, RETOPIA SALON plans to conduct a large-scale global audition tour across 18 cities worldwide, including Japan (Sendai, Okinawa, Osaka, Kyoto, Tokyo, Chiba, Fukuoka), Indonesia (Jakarta, Bandung), Thailand (Bangkok, Chiang Mai), the United States (Los Angeles, Orange County, Honolulu), and Canada (Toronto).

Further details about the auditions can be found via RETOPIA SALON’s official social media channels and local partner academies:
https://www.instagram.com/retopia.salon/

About RETOPIA SALON

RETOPIA SALON is an entertainment company founded by industry leaders who were instrumental in driving BTS’s global success during their time at HYBE. The founding team includes CEO Bang Woo Jung (former Creative Studio Leader at HYBE Media Studio), CCO Kim Serene (former VP of HYBE LABELS JAPAN), and COO Park Jun Soo (former SP at HYBE Original Content Studio).

Leveraging their extensive industry experience and expertise, the company is engaged in artist management and content production. RETOPIA SALON is currently preparing to debut its first boy group in 2027.

The team has also contributed to a range of high-profile content projects, including BTS Jin’s YouTube variety show Run Jin and the Disney+ original series Are You Sure?! Season 2 featuring Jimin and Jung Kook, drawing significant attention both within and beyond the industry.

Enhances scalable EPMS capabilities, strengthens hyperscale data center offering, and establishes a strategic foundation for Latin American growth.

• The deal expands AZZO’s ability to deliver standardized EPMS across multi-site, mission-critical portfolios
• Qubits Energy brings proven expertise in deploying energy systems for hyperscale data centers and colocation providers
• Integration with AZZO’s EnergyX® platform creates a unified solution for monitoring, control, and energy optimization
• The acquisition enhances automation capabilities through AI-enabled engineering and deployment
• AZZO gains an immediate operational footprint in Latin America via Qubits Energy’s Colombia presence
• The combined business is positioned to support rapid global growth in data center and digital infrastructure markets
• The transaction strengthens AZZO’s position in mission-critical infrastructure, where reliability and scalability are essential

NASHVILLE, Tenn., April 6, 2026 /PRNewswire/ — AZZO, a leading energy technology and services company, today announced the acquisition of Qubits Energy, a specialist in Electrical Power Management Systems (EPMS), advanced automation, and energy management solutions for data centers and other mission-critical facilities.

The acquisition expands AZZO’s ability to deliver standardized, high-performance energy management systems across global data center and critical infrastructure portfolios, while establishing a strategic foothold in Latin America.

Qubits Energy, headquartered in Nashville, Tennessee, has built a strong reputation for delivering EPMS across large, distributed environments. Its engineering-led approach enables rapid deployment, consistency across sites, and high operational reliability.

By integrating Qubits Energy’s capabilities into its EnergyX® platform, AZZO will deliver a unified architecture for monitoring, automation, and control across complex energy environments. This integration enhances AZZO’s ability to support customers operating at scale specifically in high-growth sectors such as data centers.

Qubits Energy brings established relationships with hyperscale data center owners and major colocation providers, supporting environments where uptime, scalability, and speed of deployment are critical. These capabilities complement AZZO’s EnergyX® platform and lifecycle services, positioning the combined organization to deliver consistent energy management systems across global portfolios, support rapid expansion of data center infrastructure in North America, and improve operational efficiency and reliability at scale.

The acquisition also provides AZZO with an established operational presence in Colombia, creating a foundation for growth across Latin America, a region experiencing increasing demand for digital infrastructure and energy resilience. This presence enables local engineering and delivery capabilities, supports global customers expanding into LATAM markets, and allows for scalable deployment of EnergyX® solutions across emerging data center hubs.

James DiLiberto, CEO of AZZO, said:

“Data center growth is accelerating globally, driving demand for standardized, scalable energy management solutions. Qubits Energy has demonstrated the ability to deliver these systems across complex, multi-site environments. By combining their expertise with AZZO’s EnergyX® platform and lifecycle services, we can offer a unified solution to support the next generation of mission-critical infrastructure.”

Ivan Ospina, CEO of Qubits Energy, added:

“Joining AZZO enables us to expand our reach and deliver our EPMS and automation capabilities on a global scale. Together, we are well positioned to provide intelligent, standardized energy systems to some of the world’s most demanding data center environments.”

Qubits Energy’s team and solutions will be integrated into AZZO immediately. AZZO plans to accelerate investment in AI-driven automation and mission-critical services within its EnergyX® platform.

About AZZO

AZZO is an energy technology and services company that helps customers manage complex energy ecosystems. With over 20 years of experience, AZZO specializes in microgrids and energy management for critical infrastructure. Its EnergyX® platform provides real-time visibility, control, and analytics to deliver energy resilience, improved economics, and operational flexibility. For more information, please visit www.azzo.com.

About Qubits Energy

Qubits Energy delivers standardized Electrical Power Management Systems (EPMS) for mission-critical facilities, with a focus on multi-site data center environments. Its engineering-led approach and automation capabilities enable consistent, high-performance implementations across global portfolios. For more information, please visit www.qubitsenergy.com.

Enhances scalable EPMS capabilities, strengthens hyperscale data center offering, and establishes a strategic foundation for Latin American growth.

• The deal expands AZZO’s ability to deliver standardized EPMS across multi-site, mission-critical portfolios
• Qubits Energy brings proven expertise in deploying energy systems for hyperscale data centers and colocation providers
• Integration with AZZO’s EnergyX® platform creates a unified solution for monitoring, control, and energy optimization
• The acquisition enhances automation capabilities through AI-enabled engineering and deployment
• AZZO gains an immediate operational footprint in Latin America via Qubits Energy’s Colombia presence
• The combined business is positioned to support rapid global growth in data center and digital infrastructure markets
• The transaction strengthens AZZO’s position in mission-critical infrastructure, where reliability and scalability are essential

NASHVILLE, Tenn., April 6, 2026 /PRNewswire/ — AZZO, a leading energy technology and services company, today announced the acquisition of Qubits Energy, a specialist in Electrical Power Management Systems (EPMS), advanced automation, and energy management solutions for data centers and other mission-critical facilities.

The acquisition expands AZZO’s ability to deliver standardized, high-performance energy management systems across global data center and critical infrastructure portfolios, while establishing a strategic foothold in Latin America.

Qubits Energy, headquartered in Nashville, Tennessee, has built a strong reputation for delivering EPMS across large, distributed environments. Its engineering-led approach enables rapid deployment, consistency across sites, and high operational reliability.

By integrating Qubits Energy’s capabilities into its EnergyX® platform, AZZO will deliver a unified architecture for monitoring, automation, and control across complex energy environments. This integration enhances AZZO’s ability to support customers operating at scale specifically in high-growth sectors such as data centers.

Qubits Energy brings established relationships with hyperscale data center owners and major colocation providers, supporting environments where uptime, scalability, and speed of deployment are critical. These capabilities complement AZZO’s EnergyX® platform and lifecycle services, positioning the combined organization to deliver consistent energy management systems across global portfolios, support rapid expansion of data center infrastructure in North America, and improve operational efficiency and reliability at scale.

The acquisition also provides AZZO with an established operational presence in Colombia, creating a foundation for growth across Latin America, a region experiencing increasing demand for digital infrastructure and energy resilience. This presence enables local engineering and delivery capabilities, supports global customers expanding into LATAM markets, and allows for scalable deployment of EnergyX® solutions across emerging data center hubs.

James DiLiberto, CEO of AZZO, said:

“Data center growth is accelerating globally, driving demand for standardized, scalable energy management solutions. Qubits Energy has demonstrated the ability to deliver these systems across complex, multi-site environments. By combining their expertise with AZZO’s EnergyX® platform and lifecycle services, we can offer a unified solution to support the next generation of mission-critical infrastructure.”

Ivan Ospina, CEO of Qubits Energy, added:

“Joining AZZO enables us to expand our reach and deliver our EPMS and automation capabilities on a global scale. Together, we are well positioned to provide intelligent, standardized energy systems to some of the world’s most demanding data center environments.”

Qubits Energy’s team and solutions will be integrated into AZZO immediately. AZZO plans to accelerate investment in AI-driven automation and mission-critical services within its EnergyX® platform.

About AZZO

AZZO is an energy technology and services company that helps customers manage complex energy ecosystems. With over 20 years of experience, AZZO specializes in microgrids and energy management for critical infrastructure. Its EnergyX® platform provides real-time visibility, control, and analytics to deliver energy resilience, improved economics, and operational flexibility. For more information, please visit www.azzo.com.

About Qubits Energy

Qubits Energy delivers standardized Electrical Power Management Systems (EPMS) for mission-critical facilities, with a focus on multi-site data center environments. Its engineering-led approach and automation capabilities enable consistent, high-performance implementations across global portfolios. For more information, please visit www.qubitsenergy.com.